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People who inject drugs are at increased risk of acquiring HIV and accounted for 10% of 
all new diagnoses in 2018. Pre-exposure prophylaxis has been shown to reduce HIV 
acquisition among at-risk populations, including people who inject drugs. However, pre-
exposure prophylaxis is underutilized by people who inject drugs due to limited 
knowledge about its existence and purpose. The objective of this study is to determine 
the effectiveness of a patient navigation intervention in increasing initiation of pre-
exposure prophylaxis among people who inject drugs. Specifically, we will carry out a 
randomized controlled study to compare the rates of pre-exposure prophylaxis initiation 
among individuals receiving an informational pamphlet or a multi-session intervention 
with a PrEP navigator. The results of this study will serve to determine whether an in-
person patient navigation intervention is an effective strategy to improve pre-exposure 
prophylaxis initiation among people who inject drugs.  
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CHAPTER 1: INTRODUCTION 
1.1 Background: 
1.1.1 HIV among People Who Inject Drugs 
In the United States, people who inject drugs (PWID) are disproportionately 
affected by HIV—constituting about 3% of adults in the general population but 
accounting for 10% of all new HIV diagnoses in 2018.1,2 The current national opioid 
epidemic has led to greater numbers of PWID, thereby putting new populations at higher 
risk for contracting HIV.3 Of the nearly one million people in the United states living 
with a diagnosed HIV infection in 2016, 10% of infections in males and 21% of 
infections in females were attributed to injection drug use.4  
Pre-exposure prophylaxis (PrEP) has been shown to reduce the risk of HIV 
acquisition in at-risk populations, including PWID.5,6 PrEP is a medication that comes in 
two formulations, consisting of tenofovir (TDF or TAF) and emtricitabine (FTC) in a 
fixed-dose combination that is taken orally once a day.5 The Centers for Disease Control 
and Prevention (CDC) recommends PrEP as one HIV prevention option in adult PWID 
based on the risks associated with sharing injection equipment and sexual behaviors such 
as unprotected sex.5,7,8 The indications for PrEP in adult PWID are that they must be (1) 
HIV-negative, (2) have injected non-prescription drugs in the last six months, and either 
a) have shared injection or drug preparation equipment in the past six months or b) are at 
risk for sexual acquisition.5 Sexual risks include sex without condoms, sexual partners of 
unknown or positive HIV status, or a bacterial sexually transmitted infection (STI) in the 
past 6 months.5 Despite the CDC’s recommendations that PrEP be provided to PWID at 
substantial risk for HIV, there has been limited uptake.2  
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While it can be challenging to engage PWID in preventive services within routine 
medical settings, community-based harm reduction agencies are sites regularly accessed 
by PWID and may offer a potential solution.9 Harm reduction refers to patient-centered 
programs and practices that seek to reduce the potential adverse health consequences of 
illicit drug use. For example, syringe exchange programs (SEPs) provide sterile injection 
equipment and syringes to people actively using drugs and serve to decrease the 
transmission of infectious diseases, such as HIV.10 Harm reduction programs thus can be 
used as avenues for PrEP delivery due to their common goal of limiting HIV acquisition.   
Despite the key role that harm reduction services play in risk reduction, their 
presence alone is not sufficient to prevent HIV. From 2015-2017, approximately 11% of 
HIV-positive PWID engaged in distributive syringe sharing, which means that they gave 
their used syringes to another person for use.11 Additionally, compared to HIV-positive 
people who do not inject drugs, HIV-positive PWID were more likely to have a 
detectable viral load (48% vs. 35%, p=0.008) and more likely to engage in high risk sex 
(p<0.001).11  This demonstrates that HIV-positive PWID are contributing to the spread of 
HIV among their HIV-negative peers.  
According to the National HIV Behavioral Surveillance (NHBS) 2015 data, 27% 
of HIV-negative PWID receptively shared syringes, 49% receptively shared injecting 
equipment, and 67% had condomless vaginal sex in the previous 12 months.8 Overall, 
72% had engaged in condomless heterosexual sex or receptive needle sharing during the 
surveillance period, which are factors strongly associated with HIV infection.3,7,8 During 
that same time frame, 58% received HIV testing and 52% received syringes from a SEP.8 
These various HIV risk behaviors make PWID up to 22 times more likely to acquire HIV 
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compared to the general population in the United States.12 These statistics demonstrate 
that despite the presence of harm reduction services such as SEPs, PWID are still at risk 
for acquiring HIV through injection practices and sexual behaviors. This emphasizes the 
need for further harm reduction efforts and the opportunity for the introduction of PrEP 
as part of the range of services offered to PWID who are already accessing SEPs. 
1.1.2 Current Trends in PrEP Use Among People Who Inject Drugs 
The need for PrEP promotion and uptake among PWID has been strongly 
encouraged by organizations such as the CDC, the National Institutes of Health (NIH), 
and the United States Preventive Services Task Force (USPSTF).5,13,14  In 2015, the CDC 
estimated that 18.5% of PWID had substantial risks for acquiring HIV consistent with 
indications for PrEP use.15 In a study looking at real-world eligibility for PrEP among 
Canadian PWID, 37% of participants were eligible for PrEP according to CDC 
guidelines.16 Despite PrEP eligibility, systematic review and meta-analysis describing 
PrEP use among key populations has found that PWID reported the lowest PrEP use 
compared to other key populations such as men who have sex with men (MSM), 
Hispanics/Latinos, and transgender women.12  
To date, there has only been one efficacy trial evaluating PrEP among PWID. 
Results of this randomized, double-blind, placebo-controlled Bangkok Tenofovir Study 
(BTS) showed a 49% reduction in HIV incidence (95% CI 9.6-72.2; p=0.01) in 2,413 
PWID from methadone clinics taking once daily PrEP compared to placebo.6 The 
reduction rate increased to as high as 83% (95% CI 40-98) for those with the highest 
amounts of medication adherence (97.5% adherence).17 However, even moderate 
adherence of five or more of days per week without missing more than two consecutive 
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doses showed a 73.5% reduction in HIV acquisition (95% CI 16.6-94.0; p=0.03).6 These 
findings publicized the efficacy of PrEP and led the CDC to endorse PrEP to prevent HIV 
acquisition in PWID in 2013.18 In a one-year open label extension to the BTS study, 
returning participants were offered one year of daily tenofovir for PrEP.19  Of the 1,315 
eligible participants, 61% chose to start PrEP.19 This high participation rate indicates that 
a majority of PWID who are knowledgeable about PrEP may be interested in taking it 
once they are aware of its role in preventing HIV. Additionally, participants who injected 
heroin (OR 1.5, 95% CI 1.1-2.1, p=0.007) or had been in prison (OR 1.7, 95% CI 1.3-2.1, 
p<0.0001) were more likely to choose PrEP than participants without those 
characteristics.19 This suggests that participants may have based their decision to initiate 
PrEP on their perceived risk of HIV infection.19  
Despite the demonstrated success of PrEP in PWID, available data suggest that 
PrEP awareness and use are low among PWID.2,13 According to the 2015 NHBS data on 
injection drug use patterns in 20 U.S cities, only 9.7% of the 9,675 HIV-negative PWID 
surveyed had ever heard of PrEP.20 Even more striking is that only 0.3% had taken PrEP 
at any point during the 12 months before the interview.20 According to interviews with a 
number of key informants and HIV-negative PWID, limited PrEP knowledge and 
misperceptions about the risk of acquiring HIV act as barriers for eligible PWID to 
receive recommended PrEP care.21,22 These low rates of PrEP use can be attributed in 
part to the limited awareness about PrEP in PWID, which ranges from 3-56% depending 
on the subpopulations of PWID surveyed.2,9,21,23-33 However, once informed about it, 
PWID’s interest in taking PrEP can range from 47-79%.22-26,33,34 Notably, the 56% PrEP 
awareness finding came from a qualitative study of 397 PWID in San Francisco after a 
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vigorous PrEP promotion campaign.29 The sample included PWID who were also MSM, 
and all seven male PWID who had used PrEP in the last year also identified as MSM.29 
The researchers also found that PrEP awareness and use did not differ based on frequency 
of injection or by whether the respondent had used a needle used by someone else at any 
time in the last 12 months.29 This highlights that intersectional identities surrounding 
sexuality and gender identity can overlap to increase PrEP awareness, perhaps 
irrespective of PWID status.  
 In a cross-sectional survey sample of 265 HIV-negative PWID,  90% of PrEP 
eligible participants said they believed that it would be easy to take PrEP every day, 
suggesting that PrEP adherence may be feasible.24 However, medical providers serving 
PWID may not be currently well prepared to prescribe PrEP due to their limited 
knowledge about PrEP, perception of challenges to patient access, and uncertainty about 
adherence.28,35 These provider-level barriers demonstrate the need for PWID to become 
empowered about PrEP as they may not necessarily be getting offered PrEP by their 
providers. Therefore, strategies to reach PWID and introduce PrEP in settings serving 
PWID, such as syringe exchange programs, may be effective in overcoming this barrier.35 
1.1.3 Potential for Syringe Exchange Programs as Sites for PrEP 
To date, there have been few PrEP interventions developed for actively injecting 
PWID.2,22 It has been well established that syringe exchange programs are a harm 
reduction strategy that can significantly reduce HIV prevalence and incidence among 
PWID.7,10,22,30,36,37 Individuals who acquire needles exclusively from SEPs are also 
significantly less likely to report syringe sharing (AOR 0.46, 95% CI 0.27-0.76).38 
Evidence from a systematic review and meta-analysis demonstrates that the use of SEPs 
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is associated with a 44-58% decrease in HIV transmission rates among PWID.39 SEPs are 
an essential source of sterile needles, but are also valuable settings that can offer services 
such as condom provision, drug treatment referral, overdose prevention, and HIV 
testing.7,40  
About 52% of U.S PWID report having access to syringes via SEPs.8 Research 
has shown that having conversations about HIV prevention in SEPs leads to increased 
awareness of PrEP among PWID.41 Additionally, PWID that obtain needles primarily 
from harm reduction services such as SEPs were nearly twice as likely to have awareness 
about PrEP than those who did not access these programs in the past year.2 A study 
comparing injection behaviors among PWID before and after the introduction of SEPs 
found that they led to a decrease in overall receptive/distributive syringe sharing (75% 
before vs. 21% after, p<0.05), particularly among HIV-positive persons (90% vs. 9%, 
p<0.05, respectively).42 This suggests that SEPs are an effective harm reduction tool that 
can decrease the HIV transmission risk among PWID by increasing PrEP awareness and 
promoting safer injection drug practices.  
Previous studies have recommended the integration of educational efforts about 
PrEP into existing services for PWID, such as SEPs, along with facilitated access to 
PrEP.24,33,34,43-45 Qualitative research also suggests that PWID have high levels of trust in 
SEPs, due to the ways in which they create a stigma-free environment.46,47 In a cross-
sectional study of 138 PWID evaluating PrEP eligibility and access among SEP users, 
86% of participants reported that they would prefer to access HIV screening from a SEP 
rather than a STI clinic, indicating that SEPs may be a viable access point to connect 
PWID to PrEP.34 Despite utilization of SEPs where participants presumably go to access 
 7 
harm reduction supplies, this same study reported that 45% of PWID still engaged in 
high-risk injection behaviors, such as needle sharing.34 In another cross-sectional study of 
1,445 PWID recruited from California SEPs, researchers found that a sizeable majority of 
the sample was sexually active, had multiple sexual partners, and did not use condoms 
consistently for anal, vaginal, or oral sex.48 These risky sexual behaviors tended to co-
occur with high levels of syringe sharing behaviors, despite participation in SEPs.48  
These overlapping patterns of sexual and injection related HIV risk behaviors 
have also been well described in a qualitative study of Northeast PWID. This study found 
that the three predominant contexts in which these high risk behaviors occur are through 
multiple concurrent sexual partnerships, injecting drugs with sexual partners, and 
exchanging sex for money.49 Since sexual risk behaviors are also an important driver of 
HIV infections among PWID, SEPs alone are not enough to protect PWID who are also 
engaging in HIV sexual risk behaviors.49 This highlights that the introduction of PrEP 
into SEPs could be a valuable supplemental strategy in the goal of reducing HIV 
infections among PWID. 
1.2 Statement of the Problem:  
PWID are a population at increased risk for HIV acquisition due to risk factors 
such as injection drug practices and unprotected sexual intercourse.5 PrEP is a medication 
that can significantly reduce the risk of contracting HIV in PWID by as much as 83%.17 
Despite the benefits of PrEP, as little as 3% of PWID may know about its existence and 
purpose in preventing HIV, leading to underutilization among PrEP-eligible PWID.26 
There have been a number of qualitative studies evaluating PWID’s perceptions and 
interest in PrEP, but to date there have been a limited number of studies evaluating 
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interventions to increase PrEP uptake among PWID.2,9,21-26,50 This lack of research has 
resulted in a gap in the literature about effective strategies to increase PrEP initiation 
among PWID. Patient navigation has emerged as a potentially effective strategy applied 
separately to PWID to increase linkage to HIV care and promote PrEP uptake among 
diverse HIV-negative populations.51,52 However, to the best of our knowledge, there have 
not been any published studies evaluating the effect of patient navigation on PrEP 
initiation in populations of PWID.13 Furthermore, despite PWID’s preferences and 
utilization of harm reduction programs, there is a lack of studies which have specifically 
sought to engage PWID accessing harm reduction programs for PrEP education and 
intervention.10,34 Therefore, we propose a randomized controlled trial (RCT) in four SEPs 
to evaluate the effect of a patient navigation intervention on PrEP initiation rates among 
PWID after 12 weeks. The results gained by this novel study have the potential to provide 
a framework for future interventions to promote PrEP initiation among PWID. 
1.3 Goals and Objectives: 
The overall objective of this study is to educate and link participants to PrEP to 
increase the amount of eligible PWID who have initiated PrEP medication within 12 
weeks of the intervention. This RCT will compare two PrEP education delivery formats, 
a PrEP information pamphlet (control) vs. a PrEP pamphlet plus patient navigation 
(intervention), to assess if there is a significant difference in PrEP initiation rates between 
the two groups. To address the lack of PrEP uptake among PWID, all participants 
regardless of group allocation will receive the PrEP pamphlet. The pamphlet will discuss 
the risk behaviors associated with acquiring HIV, risk reduction techniques, the role of 
PrEP in HIV prevention, information on local PrEP providers, and financial resources for 
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covering the costs associated with PrEP. The intervention group will additionally receive 
a patient navigation intervention based on motivational interviewing and strengths-based 
case management (SBCM) models to explore interest and perceived barriers to initiating 
PrEP. The intervention will consist of a 45-60 minute one-on-one session with a PrEP 
navigator within a SEP. These participants will be offered up to four follow up sessions 
with the PrEP navigator to address any additional PrEP related concerns. The control 
group will only receive the PrEP pamphlet as the enhanced standard of care condition. In 
addition, assessments at baseline and 12-week follow-up will examine PrEP awareness, 
HIV risk behaviors, perception of HIV risk, and likelihood of starting PrEP. 
The primary outcome will be the rates of PrEP initiation within 12 weeks of the 
intervention among both groups of participating PWID in the SEP setting. PrEP initiation 
rates will be assessed using self-report and confirmatory tenofovir urine testing. 
Secondary outcomes include the comparison of results from pre and post intervention 
assessments. An exploratory outcome will be sustained adherence to PrEP, measured via 
self-report and tenofovir dried blood spots (DBS) confirmation, 18 weeks after 
randomization. The results of this study will determine the added impact of patient 
navigation to a PrEP educational pamphlet to promote PrEP initiation among PWID 
accessing syringe exchange programs.  
1.4 Hypothesis: 
Among PWID accessing syringe exchange programs, we hypothesize that the 
intervention group with PrEP discussion facilitated by a PrEP navigator will result in a 
12-week PrEP initiation absolute rate difference of 15% compared to the enhanced 
standard of care control group. 
 10 
1.5 References:  
 
1. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses 
of HIV Infection in the United States and Dependent Areas, 2018 (Preliminary).  
Published November 2019. 
2. Roth A, Tran N, Piecara B, Welles S, Shinefeld J, Brady K. Factors Associated 
with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject 
Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. AIDS Behav. 
2019;23(7):1833-1840. 
3. Centers for Disease Control and Prevention. HIV and people who inject drugs. 
https://www.cdc.gov/hiv/group/hiv-idu.html. Published 2019. Updated November 
12, 2019. Accessed December 9, 2019. 
4. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses 
of HIV Infection in the United States and Dependent Areas, 2017.  Published 
November 2018. 
5. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the 
Prevention of HIV Infection in the United States. 2017 Update: Clinical Practice 
Guideline.  Published March 2018. 
6. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for 
HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok 
Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. 
Lancet. 2013;381(9883):2083-2090. 
7. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-
injecting drug users: current trends and implications for interventions. Current 
HIV/AIDS reports. 2010;7(2):99-106. 
8. Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV Infection and 
HIV-Associated Behaviors Among Persons Who Inject Drugs - 20 Cities, United 
States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(1):23-28. 
9. Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure 
prophylaxis (PrEP) among women who inject drugs in NYC: the importance of 
networks and syringe exchange programs for HIV prevention. Harm Reduct J. 
2017;14(1):40. 
10. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV 
and Hepatitis C in people who inject drugs: a review of reviews to assess evidence 
of effectiveness. The International journal on drug policy. 2014;25(1):34-52. 
11. Dasgupta ST, Y.; Lemons, A.; Wu, K.; Burnett, J.; Shouse, RL. Injection 
Practices and Sexual Behaviors Among Persons with Diagnosed HIV Infection 
Who Inject Drugs — United States, 2015–2017. MMWR Morb Mortal Wkly Rep. 
2019;68(30). 
12. Kamitani E, Johnson WD, Wichser ME, Adegbite AH, Mullins MM, Sipe TA. 
Growth in proportion and disparities of HIV PrEP use among key populations 
identified in the United States national goals: systematic review & meta-analysis 
of published surveys. J Acquir Immune Defic Syndr. 2020. 
13. National Institutes of Health. PrEP for HIV Prevention among Substance Using 
Populations. In: National Institute on Drug Abuse; 2019. 
 11 
14. U. S. Preventive Services Task Force. Preexposure Prophylaxis for the Prevention 
of HIV Infection: USPSTF Recommendation Statement. JAMA. 
2019;321(22):2203-2213. 
15. Smith DK, Van Handel M, Wolitski RJ, et al. Vital Signs: Estimated Percentages 
and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent 
HIV Acquisition--United States, 2015. J Miss State Med Assoc. 2015;56(12):364-
371. 
16. Picard J, Jacka B, Hoj S, et al. Real-World Eligibility for HIV Pre-exposure 
Prophylaxis Among People Who Inject Drugs. AIDS Behav. 2020. 
17. Martin M, Vanichseni S, Suntharasamai P, et al. The impact of adherence to 
preexposure prophylaxis on the risk of HIV infection among people who inject 
drugs. Aids. 2015;29(7):819-824. 
18. Kennedy C, Fonner V, World Health O. Pre-exposure prophylaxis for people who 
inject drugs: a systematic review. Geneva: World Health Organization; 2014 
2014. 
19. Martin M, Vanichseni S, Suntharasamai P, et al. Factors associated with the 
uptake of and adherence to HIV pre-exposure prophylaxis in people who have 
injected drugs: an observational, open-label extension of the Bangkok Tenofovir 
Study. Lancet HIV. 2017;4(2):e59-e66. 
20. Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and 
Testing Behaviors among Persons Who Inject Drugs — National HIV Behavioral 
Surveillance Injection Drug Use, 20 U.S. Cities, 2015.  Published May 2018. 
21. Bazzi AR, Biancarelli DL, Childs E, et al. Limited Knowledge and Mixed Interest 
in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject 
Drugs. AIDS Patient Care STDS. 2018;32(12):529-537. 
22. Biello KB, Bazzi AR, Mimiaga MJ, et al. Perspectives on HIV pre-exposure 
prophylaxis (PrEP) utilization and related intervention needs among people who 
inject drugs. Harm Reduct J. 2018;15(1):55. 
23. Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure 
prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694-1700. 
24. Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and 
interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol 
Depend. 2019;195:148-155. 
25. Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis 
among community-recruited, older people who inject drugs in Washington, DC. 
Drug Alcohol Depend. 2016;164:8-13. 
26. Escudero DJ, Kerr T, Wood E, et al. Acceptability of HIV Pre-exposure 
Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian 
Setting. AIDS Behav. 2015;19(5):752-757. 
27. Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness 
to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-
Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in 
Treatment. AIDS Behav. 2017;21(5):1299-1308. 
28. Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a 
qualitative study of treatment provider perspectives. Subst Abuse Treat Prev 
Policy. 2015;10:1. 
 12 
29. McFarland W, Lin J, Santos GM, Arayasirikul S, Raymond HF, Wilson E. Low 
PrEP Awareness and Use Among People Who Inject Drugs, San Francisco, 2018. 
AIDS and Behavior. 2019. 
30. Ranjit YS, Shrestha R, Copenhaver M, Altice FL. Online HIV information 
seeking and pre-exposure prophylaxis awareness among people who use drugs. 
Journal of substance abuse treatment. 2020;111:16-22. 
31. Shrestha R, Karki P, Altice FL, et al. Measuring Acceptability and Preferences for 
Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An 
Application to Primary HIV Prevention Among High Risk Drug Users. AIDS and 
Behavior. 2018;22(4):1228-1238. 
32. Zhang C, McMahon J, Simmons J, Brown LL, Nash R, Liu Y. Suboptimal HIV 
Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women 
Who Use Drugs in the United States: A Systematic Review and Meta-analysis. 
AIDS Behav. 2019;23(10):2641-2653. 
33. Jo Y, Bartholomew TS, Doblecki-Lewis S, et al. Interest in linkage to PrEP 
among people who inject drugs accessing syringe services; Miami, Florida. PLOS 
ONE. 2020;15(4):e0231424. 
34. Roth AM, Aumaier BL, Felsher MA, et al. An Exploration of Factors Impacting 
Preexposure Prophylaxis Eligibility and Access Among Syringe Exchange Users. 
Sex Transm Dis. 2018;45(4):217-221. 
35. Edelman EJ, Moore BA, Calabrese SK, et al. Primary Care Physicians' 
Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject 
Drugs. AIDS Behav. 2017;21(4):1025-1033. 
36. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. 
Prevention of HIV infection for people who inject drugs: why individual, 
structural, and combination approaches are needed. Lancet. 2010;376(9737):285-
301. 
37. Rich KM, Bia J, Altice FL, Feinberg J. Integrated Models of Care for Individuals 
with Opioid Use Disorder: How Do We Prevent HIV and HCV? Current 
HIV/AIDS reports. 2018;15(3):266-275. 
38. Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high-
risk syringe sharing in the presence of an established needle exchange 
programme. AIDS. 2002;16(6):941-943. 
39. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes 
associated with a reduction in HIV transmission among people who inject drugs: a 
systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235-248. 
40. Strike C, Miskovic M. Scoping out the literature on mobile needle and syringe 
programs-review of service delivery and client characteristics, operation, 
utilization, referrals, and impact. Harm Reduct J. 2018;15(1):6. 
41. Walters SM, Coston B, Neaigus A, et al. The role of syringe exchange programs 
and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male 
persons who inject drugs. The International journal on drug policy. 
2020;77:102671. 
42. Dasgupta S, Broz D, Tanner M, et al. Changes in Reported Injection Behaviors 
Following the Public Health Response to an HIV Outbreak Among People Who 
Inject Drugs: Indiana, 2016. AIDS Behav. 2019;23(12):3257-3266. 
 13 
43. Bazzi AR, Drainoni ML, Biancarelli DL, et al. Systematic review of HIV 
treatment adherence research among people who inject drugs in the United States 
and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence 
interventions. BMC Public Health. 2019;19(1):31. 
44. Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis 
for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 
2012;7(6):563-568. 
45. Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure 
prophylaxis for people who inject drugs: a review of current results and an agenda 
for future research. J Int AIDS Soc. 2014;17:18899. 
46. Hershow RB, Gonzalez M, Costenbader E, Zule W, Golin C, Brinkley-Rubinstein 
L. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis 
for HIV Prevention Among People Who Inject Drugs. AIDS Education and 
Prevention. 2019;31(4):363-379. 
47. Treloar C, Rance J, Yates K, Mao L. Trust and people who inject drugs: The 
perspectives of clients and staff of Needle Syringe Programs. The International 
journal on drug policy. 2016;27:138-145. 
48. Bogart LM, Kral AH, Scott A, et al. Sexual risk among injection drug users 
recruited from syringe exchange programs in California. Sexually Transmitted 
Diseases. 2005;32(1):27-34. 
49. Edeza A, Bazzi A, Salhaney P, et al. HIV Pre-exposure Prophylaxis for People 
Who Inject Drugs: The Context of Co-occurring Injection- and Sexual-Related 
HIV Risk in the U.S. Northeast. Substance Use and Misuse. 2019. 
50. Koechlin FM, Fonner VA, Dalglish SL, et al. Values and Preferences on the Use 
of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple 
Populations: A Systematic Review of the Literature. AIDS Behav. 
2017;21(5):1325-1335. 
51. Samet JH, Blokhina E, Cheng DM, et al. A strengths-based case management 
intervention to link HIV-positive people who inject drugs in Russia to HIV care. 
Aids. 2019;33(9):1467-1476. 
52. Doblecki-Lewis S, Butts S, Botero V, Klose K, Cardenas G, Feaster D. A 
Randomized Study of Passive versus Active PrEP Patient Navigation for a 
Heterogeneous Population at Risk for HIV in South Florida. J Int Assoc Provid 
AIDS Care. 2019;18:2325958219848848. 
 14 
 
CHAPTER 2: REVIEW OF THE LITERATURE  
2.1 Introduction: 
We conducted a thorough review of the literature between December 2019-May 2020 
using Ovid (Medline), Pubmed, Scopus, and Web of Science. Only articles in English 
were evaluated. Review of titles and abstracts determined their relevance to the proposed 
study. Key terms used in each database to extract articles pertaining to the study 
population and intervention were: people who inject drugs (injection drug use, persons 
who inject drugs, intravenous drug use, PWID, IDU, IVDU), and pre-exposure 
prophylaxis (preexposure prophylaxis, PrEP). Terms used to identify any overlap 
between the study setting and intervention were: syringe exchange program (needle 
exchange program, needle syringe program, syringe services program) and pre-exposure 
prophylaxis (preexposure prophylaxis, PrEP). Terms used to identify model PrEP 
navigation studies included: pre-exposure prophylaxis (preexposure prophylaxis, PrEP) 
and navigator (navigation, educator, coordinator) or “case management”(“case 
manager”) or “PrEP navigator.” We used combinations of keywords for PWID and 
navigation to find studies that applied a patient navigation strategy in populations of 
people who inject drugs. Terms used to find articles on PrEP initiation combined the 
terms describing PrEP and PWID with initiation OR uptake. Controlled vocabulary terms 
included a combination of (drug users or substance abuse, intravenous or people who 
inject drugs) and (pre-exposure prophylaxis or anti-HIV agents) and (syringe exchange 
program or needle-exchange programs or harm reduction).  
2.2 Review of Empirical Studies: 
2.2.1 Patient Navigation as an Intervention in HIV Care  
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Patient navigation is a patient-centered healthcare strategy increasingly applied to 
HIV care in order to promote access and reduce barriers to services that improve health 
outcomes.1,2 This model of care shares some commonalities with the roles of health 
educators, case managers and social workers.2 In a qualitative meta-synthesis by Roland 
et al., clients reported that navigators provided support for HIV and social service needs, 
increased engagement and adherence in care, and promoted self-efficacy.3 While there is 
no single definition for the role of a patient navigator nor a protocol for how their 
services should best be applied, patient navigation shows promise in improving HIV care 
continuum outcomes.1 In a systematic review performed by Mizuno et al., five out of the 
six studies reported a positive association between patient navigation and linkage to HIV 
care.1 When translated into HIV-prevention, patient navigation can be evaluated in the 
context of the PrEP care continuum, which includes three main categories (Figure 1).4,5 
Similarly to HIV patient navigators, PrEP navigators have emerged as an intervention to 
increase mobility through the PrEP continuum and improve PrEP implementation.6 In a 
prospective study of 187 transgender women and MSM, approximately 90% were linked 
to PrEP via a peer navigator program over a 90-day intervention period.7   
 
Figure 1: PrEP Care Continuum4,5 
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Additionally, a pilot study of 61 adults interested and eligible for PrEP 
randomized participants to either a patient navigation intervention or a passive referral for 
PrEP, with the goal of increasing PrEP linkage and initiation.8 Overall 40% of the 
intervention group and 29% of the control group initiated PrEP by 12 weeks (p=0.37). 
The patient navigation intervention used a strengths-based case management model in 
which the navigator supported the participants’ abilities and assets and helped them 
identify PrEP resources in the community. The goal of this strategy was to counter 
indifferent attitudes regarding linkage to prevention services and encourage positive 
engagement in the process.8 While this study only included two participants who had 
engaged in injection drug use in the last 90 days, it is a model of an intervention used to 
increase PrEP initiation through patient navigation. It is important to note that this study 
began with a small sample size and then had a 50% loss to follow up in both the 
intervention and control groups. All individuals who were randomized were included in 
the analysis and those lost to follow up were assumed to have not reached the study 
endpoints. This huge loss is likely the reason why the difference in PrEP initiation 
between both groups was not statistically significant.8 This pilot study highlights the need 
for further research with a more substantial study sample and recruitment of PWID to 
determine the impact of patient navigation on PrEP initiation.  
One patient navigation study that has been operationalized across diverse settings 
is the Antiretroviral Treatment Access Study (ARTAS).9 ARTAS was a RCT of 316 
recently diagnosed HIV-infected persons randomized to either the standard of care 
(passive referral) or SBCM for linkage to nearby HIV clinics. The primary outcome was 
self-reported attendance at an HIV clinic at least twice over a 12-month period. The 
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results of the study showed a higher proportion of participants in the intervention group 
visited an HIV clinician at least twice within 12 months (64% vs. 49%, RRadj 1.41, 
p=0.006).9 This study showed that offering a brief patient navigation intervention of five 
sessions or fewer is a tangible and promising strategy in promoting treatment uptake. 
While PWID made up approximately 10% of each group, the rates of treatment linkage in 
each subgroup were not described.9 Notably, ARTAS did not specifically address 
PWID’s needs, and found less effectiveness for those injecting drugs, suggesting the need 
for accommodations to support PWID. Despite ARTAS’s limited application to the target 
population of our study, the intervention is a marker for the potential success of patient 
navigation in linkage to care. Using linkage to care as an outcome, this intervention can 
also be applied to PrEP care and initiation. ARTAS has been adapted in a number of 
other studies and applied to increase the engagement of PWID in care and promote PrEP 
linkage and initiation.7,8,10,11 All studies demonstrated success in their patient navigation 
interventions and reached their respective primary objectives.  
A key study that challenged the efficacy of patient navigation was a multi-site 
RCT of 801 hospitalized participants with comorbid substance use and elevated HIV viral 
loads.12 Researchers evaluated the effect of a structured patient navigation intervention 
with or without financial incentives to improve HIV viral suppression rates. Patient 
navigation included up to 11 sessions of care coordination with SBCM and motivational 
interviewing. Financial incentives of up to $1,160 were provided for achieving target 
behaviors aimed at reducing substance use and improving HIV outcomes. The control 
group received the standard practice of the respective 11 hospitals for linking hospitalized 
patients to HIV care and substance use treatment. Results of the study showed no 
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differences in rates of HIV viral suppression versus non-suppression among the 3 groups 
at 12 months.12 However, the study had a number of limitations in the context of our 
proposed intervention. First, the study did not focus primarily on PWID and only 18.4% 
of participants reported injection drug use in the prior year. While participants did have 
substance use disorders, a majority used stimulants, which is associated with a lower 
likelihood of becoming virally suppressed compared to those who use opiates, alcohol or 
both.12 Additionally, several study sites were not located in areas with harm reduction 
services and there were inconsistent addiction treatment options for participants.12 These 
limitations highlight the need for the patient navigation to be targeted towards specific 
groups of people who use drugs, along with appropriate access to treatment services.  
Multiple studies involving a patient navigation intervention have focused on 
overcoming barriers to care. To do so, they have utilized patient-centered approaches 
such as SBCM and motivational interviewing as part of the patient navigator role.2,7-9 
They have also worked to directly address financial concerns of PrEP and ancillary 
service needs such as referrals to substance use treatment or mental health counseling.7,13 
These various components of the patient navigation strategies demonstrate the diversity 
in approaches and feasibility of adapting the intervention to meet the needs of specific 
populations, such as PWID.  
2.2.2 Patient Navigation in PWID 
Patient navigation has shown success in populations of PWID and been adapted to 
achieve various outcomes. While there are no studies modeling the use of patient 
navigation to promote PrEP uptake in PWID, there are a number of studies assessing 
other health care connection outcomes, such as entry into drug treatment and 
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antiretroviral treatment (ART) initiation. In an uncontrolled prospective study in Greece 
of 45 recently HIV diagnosed PWID, 87% entered care within 2 months of the patient 
navigation intervention and 77% of those then initiated ART.14 The patient navigator had 
consistent contact with participants, assisted with appointment scheduling, helped to 
address ART access and insurance coverage, and connected participants to medical 
facilities for additional care.14 This intensive case management approach was adapted to 
meet the needs of PWID, particularly in addressing structural and administrative barriers 
such as health insurance access, legal issues, and social issues.14 While one major 
limitation to this study is its small sample size and uncontrolled design, its results report 
the role of patient navigation on the continuum of care for PWID with recent HIV 
infection. It therefore holds promise as an adaption for HIV-negative PWID at substantial 
risk for HIV who can benefit from PrEP initiation.  
Similarly, a RCT in Russia of 349 HIV-positive PWID not on ART studied the 
effect of a peer-led SBCM intervention compared to usual care (resource card with harm 
reduction and HIV care information).11 The results showed that within 6 months of 
enrollment, 51% of the intervention group and 31% of the controls were linked to HIV 
care, defined by one or more visits to an HIV medical provider (AOR 2.34, 95% CI: 
1.49-3.67, p<0.001).11 It also showed that participants who attended two or more case 
management sessions or all five sessions had greater rates of linkage to HIV care when 
compared to the control group (AOR 2.57, 95% CI 1.59-4.16, p<0.0001 and 2.91, 95% 
CI 1.68-5.07, p<0.0002, respectively).11 Ninety-one percent of intervention group 
participants were very much or somewhat satisfied with the case management 
intervention. Notable limitations to the generalizability of this study include that 
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participants were screened for eligibility while in an inpatient addiction hospital 1-5 days 
after admission and after treatment of withdrawal symptoms. Therefore, participants were 
in a controlled setting during their first intervention session and were not actively 
injecting drugs. While subsequent case management sessions were conducted in the 
community after hospital discharge, the intervention did not reach people who did not 
receive treatment at the narcology hospital. While both of these previously described 
studies included HIV-positive participants rather than HIV-negative, they both studied 
PWID and demonstrated the feasibility and effectiveness of applying a patient navigator 
approach to increase linkage to care.11,14  
In a vanguard RCT conducted in three cities in Ukraine, Vietnam and Indonesia, 
502 HIV-infected PWID were randomized in a 1:3 ratio to a brief case management and 
individually tailored psychosocial counseling session versus standard of care (referrals to 
ART and substance use treatment).15 The case management component included systems 
navigation, which helped participants manage logistical barriers to treatment such as 
scheduling ART or medication for addiction treatment (MAT) initiation appointments, 
assisting with medical paperwork, and answering health related questions. The systems 
navigators met with the intervention arm participants at least twice, with subsequent 
sessions tailored to the needs of the participants.15 The initial encounters with systems 
navigators were brief, with 84% lasting 30 minutes or less and a median of 3 encounters 
per person in the first 8 weeks.15 The psychosocial counseling component used 
motivational interviewing, problem solving, skills building, and goal setting to promote 
initiation of ART and MAT.15 Intervention arm participants received a minimum of two 
psychosocial counseling sessions, where the first session focused primarily on ART, and 
 21 
the second targeted ART adherence and MAT. Participants were also offered booster 
sessions which were tailored to individual needs. A majority (58%) of initial counseling 
encounters were 31-60 minutes long, and 83% of participants completed two or more 
sessions within 60 days, with a median of 7 sessions per person.15  
In all three sites, one person served as both the systems navigator and 
psychosocial counselor. After 26 weeks, 73% of the intervention group and 36% of the 
control group reported being on ART (95% CI 1.6-2.3), and 38% of the intervention 
group and 24% of the control reported being on MAT (95% CI: 1.2-2.2).15 Overall, these 
results demonstrate the positive and significant impact that a navigation and motivational 
interviewing approach can have on treatment linkage and initiation in PWID. A notable 
caveat to these results was the lack of uniformity in the effect of the intervention across 
all three sites. There was a positive intervention effect for ART and MAT initiation in 
Ukraine and Vietnam, but limited effect in Indonesia.15 This limitation could be due to 
underlying sociocultural differences among these countries, which further emphasizes the 
need for such intervention in American PWID.  
One study that targeted PWID in our setting of a SEP evaluated the effect of a 
SBCM intervention versus passive referral to drug treatment in 245 PWID seeking 
addiction treatment.16 Passive referral included a voucher with the date and time of the 
participant’s intake appointment at the drug treatment program. All participants were 
given a treatment voucher prior to their participation in the study, therefore the role of the 
case manager was primarily to facilitate treatment entry among those who had already 
received a referral. The SBCM intervention built upon each participant’s strengths by 
promoting goal setting and helping to manage their needs to achieve those goals. Being 
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each participant was already practicing harm reduction by attending a SEP, the strategy 
was to expand on this motivation. The duration and frequency of each session was based 
on the individual needs and desires of the participants. The case managers addressed 
barriers to treatment entry by assisting with transportation to the facility, childcare, social 
services, and referrals to health services. Treatment entry was defined as having attended 
the intake appointment for opioid agonist therapy within 7 days of the baseline interview. 
Within 7 days, 40% of the intervention group versus 26% of the control group entered 
treatment (p=0.03).16 The median duration of case management sessions were 25 
minutes, but participants who received 30 minutes or more of case management within 7 
days were 33% more likely to enter treatment.16 There was a median of two contacts with 
the case manager per participant. Factors significantly associated with entering treatment 
included: having two or more contacts with a case manager prior to the intake visit (OR 
2.46, 95% CI:1.33-4.59), spending more time with the case manager, or being driven to 
treatment by a case manager (OR 4.94, 95% CI: 2.19- 11.4).16  
Notably, this study population consisted of PWID already seeking drug treatment 
from the SEP, which means that these participants were already a motivated subgroup of 
PWID. However, rates of drug treatment entry were still low overall, demonstrating that 
entering treatment can still be difficult. This could have been due to the short 7-day 
window in which participants were considered to have entered treatment. It is possible 
that a longer timeframe could have allowed for more arrangements to be made for 
treatment entry. In an attempt to identify the mechanism through which the intervention 
facilitated treatment entry, the “intention to treat” and “as treated” models both found that 
transportation assistance was the most important factor (AOR 4.99, 95% CI 1.98-12.56, 
 23 
and AOR 3.89, p=0.03, respectively). This suggests that transportation can be an 
enormous barrier for PWID seeking to access treatment and should be considered as a 
component in a patient navigation strategy.16 The findings of this study demonstrate that 
it is possible to implement a patient navigation strategy within the SEP setting in PWID. 
While the outcome of this intervention is not our primary outcome of increasing PrEP 
initiation in PWID, it showed that a similar intervention in our study population and 
setting are feasible and can show success. This suggests that there is a benefit to offering 
integrated treatment referrals and case management services from within a SEP.  
Another iteration of this intervention is a RCT of 557 Hispanic PWID in Puerto 
Rico. Researchers implemented a combined counseling and case management behavioral 
intervention which used motivational interviewing strategies to engage participants in 
drug treatment, reduce drug use, and reduce injection-related HIV risk behaviors.17 
Participants in the experimental arm were nearly twice as likely to enter drug treatment 
(OR=1.85, 95% CI 1.50-2.74) and half as likely to continue drug injection (OR=0.55, 
95% CI = 0.34-0.88). Among those who continued to inject, participants in the 
experimental group were less than half as likely to share needles (OR=0.42, 95% CI = 
0.18-0.91).17 These results further reinforce that implementing a patient navigation 
intervention with components such as motivational interviewing can help increase 
linkage to care and reduce high risk HIV behaviors like needle sharing.  
Similarly, in another RCT case management intervention of 360 PWID, 98% of 
the case managed participants were admitted into substance use treatment programs, 
compared to only 57% of the intervention group (p<0.01).18 The case manager was cited 
by 87% of the intervention group participants as the major reason that access to treatment 
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was made easier.18 Case managers increased access to service providers, assisted with 
transportation to drug treatment, and provided continuity of care. Those assigned a case 
manager entered treatment in substantially greater numbers and more rapidly than clients 
who attempted to access treatment through usual routes.18  
The studies discussed throughout this section highlight the various ways in which 
patient navigation interventions have been used to connect PWID to various resources, 
such as MAT and ART. While there is no study that has directly focused on using patient 
navigation as a means of increasing PrEP initiation in PWID, current data demonstrate 
that patient navigation is feasible, well-studied, and particularly applicable to PWID and 
HIV-prevention initiatives. Therefore, our study will incorporate the successful aspects of 
the literature review into our study design to evaluate the rates of PrEP initiation in 
PWID accessing SEPs after the implementation a patient navigation intervention.  
2.3 Identifying Possible Confounding Variables: 
While reviewing related literature, we identified several confounding variables 
that we will address through our study design. First, we will use stratified randomization 
to randomize participants by insurance status and SEP site. Being uninsured has been 
consistently reported as a barrier to PrEP access, especially in PWID.19-21 Therefore, 
stratification based on insurance status (insured vs. uninsured) will ensure equal 
distribution of uninsured participants among the intervention and control groups. 
Stratification by SEP site is another important criterion because the services provided at 
each SEP can vary based on location and the resources that they have available. 
Previous RCTs on patient navigation have sought to assess whether 
randomization was successful and identify any confounders by comparing the baseline 
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characteristics of participants in the intervention and control arms.8,16 Examples of 
characteristics recorded in these studies include: gender identity, sexual orientation, age, 
race/ethnicity, education level, previous knowledge of PrEP, income, employment status, 
insurance coverage, and the need for transportation assistance.8,16  
Qualitative studies exploring PrEP awareness and acceptability among PWID 
have consistently reported that willingness to use PrEP is associated with higher 
perceived HIV risk and PrEP knowledge.21,22 Studies have also reported that PrEP 
willingness is associated with younger age, no regular employment, engaging in sex 
work, multiple sexual partners, and being female.19,23 Given these findings, we will 
consider these demographic factors as potential confounders and measure them at 
baseline to ensure comparability across both groups. 
A study of sociodemographic correlates of PrEP uptake in Tennessee with a 
heterogenous population that included PWID found a significant independent association 
between age, race/ethnicity, and transmission risk on PrEP uptake.24 Transmission risk 
included male to male sexual contact, injection drug use, and high risk heterosexual 
contact.24 All of these factors have the potential to impact participants’ desire and 
determination to initiate PrEP, independent of our patient navigation strategy. For this 
reason, we will be thorough in assessing these characteristics through our baseline 
assessment. If we do find any imbalances between the control and intervention groups, 
we will adjust for any differences in our statistical analyses.  
2.4 Review of Relevant Methodology:  
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This section of the literature review discusses the methodology that is relevant to the 
proposed study. A more detailed description of the proposed study methods is discussed 
in Chapter 3.  
2.4.1 Study Setting and Design 
We will conduct a multi-site study which will include participants from four SEP 
sites in Connecticut: The Greater Hartford Harm Reduction Coalition, the New Haven 
Syringe Exchange, Apex Community Care in Danbury, and the Bridgeport Health 
Department Syringe Exchange Program. The proposed study has a multi-center design to 
ensure adequate recruitment and expand our generalizability. According to Connecticut 
Department of Public Health (DPH) surveillance data, these are cities that have high 
levels of drug overdose and HIV incidence among PWID.25,26 This data is suggestive of 
active injection drug use and the spread of HIV among PWID in Connecticut, 
demonstrating the potential for PrEP implementation within these areas. PrEP delivery is 
best optimized when provided as a part of a multicomponent package that includes safety 
monitoring, behavioral intervention, and the integration of PrEP as part of a 
comprehensive care platform.27 Our study will deliver this bundle through our PrEP 
navigation intervention, connection to PrEP services, and integration into SEPs.  
Our study will target HIV-negative PWID and help them move along the 
continuum of PrEP delivery. The key steps in the PrEP continuum include: 1) identifying 
individuals at highest risk for HIV and increasing awareness, 2) facilitating access and 
linkage to care to enhance PrEP uptake, and 3) adherence to PrEP and retention in care 
(Figure 1).4 Our focus is on the second step of this continuum, as the study inclusion 
criteria will already serve to identify PWID at risk for HIV acquisition. The steps in PrEP 
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initiation include linking individuals to a site of PrEP delivery with a PrEP provider, 
obtaining baseline laboratory testing, identifying how it will be paid for, and actually 
starting the medication.5 Connecting the participants to a PrEP provider who can perform 
the necessary baseline testing will be part of the information pamphlets provided to both 
the control and intervention groups.  
Previous studies have shown that cost can be a barrier to access of PrEP.5,28-31 
Therefore, our study design will seek to reduce this burden by providing all participants 
with information regarding the copayment assistance program offered by Gilead 
Sciences, the company that produces Truvada®, which is the brand name for the 
FTC/TDF fixed dose formulation of PrEP. Gilead’s Medication Assistance Program 
provides PrEP at no cost to individuals who earn <500% of the federal poverty level.5 
Additionally, the Connecticut DPH has a comprehensive PrEP Program Resources guide 
which outlines how to pay for PrEP.32 It highlights that Gilead offers up to $7,200 per 
year of medication co-pay assistance, regardless of financial need.32 The Connecticut 
DPH has also stated that all major health insurance companies and state-provided 
insurance in Connecticut will cover PrEP medication and the necessary medical care 
associated with it.32 Providing these resources to all participants will help minimize 
individual cost as a barrier to accessing HIV prevention services and PrEP medication.  
2.4.2 Review of Recruitment Techniques  
This study will recruit among individuals accessing services from four syringe exchange 
programs in Connecticut, as well as from peer referral. Upon review of recruitment and sampling 
techniques, the most viable option that emerged is a form of convenience sampling known as 
snowball sampling. This is a method used to engage “hard-to-reach” populations such as PWID. 
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Iterations of snowball sampling have been used in a number of previously referenced studies to 
recruit PWID.33-35 Snowballing taps into the social networks of PWID by recruiting initial small 
groups of participants and asking each one of them to identify other members who will then be 
contacted and asked to identify other potential participants, and so on.35,36 The process continues 
until a sufficient number of participants have been recruited to meet sample size requirements. 
The ideal initial participants are people with diverse demographic characteristics known to 
belong to a large network of PWID.34 One necessary condition for successful snowballing is that 
members of this hidden population know each other.36 A limitation of this method is those 
missing from the recruitment frame are likely to be those socially isolated from other members 
of the rare population.36 While we will only enroll participants who have accessed one of the 
SEP sites in the last month, a strength of our approach is that we will recruit directly from the 
SEP and complement this with peer referral to maximize outreach.  
2.4.3 Inclusion and Exclusion Criteria   
The CDC-recommended indications for PrEP use by PWID include: being >18 
years old, without acute or established HIV infection, with any injection of drugs not 
prescribed by a clinician in the past 6 months, AND at least one of the following: any 
sharing of injection or drug preparation equipment in the past 6 months or risk of sexual 
acquisition.37 Risk for sexual acquisition includes: any anal sex without condoms, a 
bacterial STI in the last 6 months, infrequent condom use with one or more partners of 
unknown HIV status or who are known to be at substantial risk for HIV infection, or an 
ongoing relationship with an HIV-positive partner.37 In addition to the CDC criteria 
above, inclusion criteria for the Doblecki-Lewis et al. study included: ability to meet the 
navigator at the research site, ability to give informed consent, willingness to provide 
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contact information, and ability to be contacted by phone.8 All participants were informed 
that they would be responsible for the cost associated with the provider visit and 
associated HIV testing per the health center’s policies.8 We will utilize both the CDC 
guidance and this prior study to inform our inclusion criteria. An additional inclusion 
criterion specific to our study is that participants must have accessed services from a SEP 
at least once in the past month.  
In previous studies, HIV-negative status has been evaluated at baseline with HIV 
antibody testing using the OraQuick Rapid HIV-1 antibody test.16,23,38 The CDC 
recommends that if a rapid antibody test is used (as opposed to antigen testing), clinicians 
should assess for nonspecific signs or symptoms of viral infection during the preceding 
month or on the day of evaluation.37 Symptoms include: fever, fatigue, myalgia, skin 
rash, headache, pharyngitis, cervical adenopathy, arthralgia, night sweats, or diarrhea.37 
Prior to PrEP initiation, participants must receive an assessment of their renal function 
and a test for hepatitis B virus (HBV) infection, because decreased renal function (i.e., 
CrCl <60 ml/min) and HBV infection are potential safety issues for the use of PrEP.37 As 
all participants in our study will need to see a PrEP provider to get a PrEP prescription, 
these additional tests will be conducted at the discretion of the PrEP provider.  
Our exclusion criteria will be modeled from a study that trialed same-day PrEP 
initiation in an STI clinic.13 Criteria includes: any known renal dysfunction, being HIV 
positive, a history of chronic HBV infection, pregnancy, indications for HIV post-
exposure prophylaxis, or any signs or symptoms consistent with an acute HIV infection 
(as listed above).13 On-site point of care urine pregnancy tests can be obtained upon 
enrollment in our study, along with the OraQuick antibody HIV test.  
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2.4.4 Randomization Techniques  
In the protocol for a study seeking to increase linkage of HIV-positive PWID  
already in addiction treatment to HIV care through a patient navigation intervention, 
researchers used stratified randomization.39 Randomization into intervention or control 
was stratified based on whether participants had seen an infectious disease clinician in the 
last 12 months prior to enrollment and on reported history of hospitalization due to HIV 
infection. The goal of stratified randomization was to ensure balance with respect to these 
potential confounders. The researchers also used a computer-generated randomization 
table to achieve blocked randomization with random block sizes for each stratum. This 
method ensures a balance in sample size across both groups and minimizes selection 
bias.40 Due to the nature of the intervention, participants and patient navigators could not 
be blinded to group assignment. The study sought to minimize measurement bias by 
having the baseline assessment administered prior to randomization and by concealing 
randomization assignment from the follow up assessors.39  
Similarly, Doblecki-Lewis et al. had participants complete an interviewer-
administered baseline survey following enrollment but prior to randomization.8 
Participants were then immediately randomized to either the patient navigation  
intervention or the enhanced standard of care control. Randomization was stratified by 
subgroups of MSM and transgender women and heterosexual men and women. 
Randomization occurred via computer-generated block randomization with randomly 
selected block sizes. Both the control and intervention groups received the first step of 
their intervention immediately after randomization, which meant that all intervention 
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participants received at least one in-person patient navigation session and all members of 
the control group received their PrEP information pamphlets.8  
In contrast, Strathdee et al. used cluster randomization.16 At the beginning of the 
study, each SEP site was randomized to receive either the case management intervention 
or the passive referral to drug treatment. About halfway through the recruitment period, 
there was a 1-month washout period in which no participants were recruited. After 
washout, the sites originally randomized to case management received the control 
condition and vice versa, until the end of enrollment. The goal of this design was to limit 
contamination of the control participants. However, this method led to an unequal 
number of subjects in each group (52% in the intervention vs. 48% in the control). 
Despite this, there were no baseline differences between the intervention and control 
groups with respect to any sociodemographic or behavioral characteristics or self-
reported barriers to access to treatment.16 While minimizing contamination is an 
important concern, for the purposes of our study design we will randomize our 
participants by individual, rather than by SEP site. This is because our study only 
includes four SEP sites and we will need to stratify participants based on potential 
confounders. Lastly, it is important to note that for all of these studies of patient 
navigation interventions, it was not possible to blind the participants given the nature of 
the intervention.  
2.4.5 Review of Successful Patient Navigation Components   
Comprehensive reviews of HIV prevention strategies in PWID have 
recommended combination prevention packages that include behavioral, structural, and 
biologic interventions in order to have the greatest impact on preventing new HIV 
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infections.41-43 According to Degenhardt et al., combining strategies such as behavioral 
interventions and SEP services to address HIV risk have the highest level of evidential 
support in reducing sexual and injection risk behaviors when compared to single 
interventions.42 With these recommendations in mind, our proposed study incorporates all 
of these criteria by designing an intervention that combines the use of evidence-based 
HIV prevention strategies of PrEP, syringe exchange programs, and patient navigation.  
Number and Length of Sessions  
In the Strathdee et al. study, factors significantly associated with a greater odds of 
entering drug treatment were randomization to the case management intervention (OR 
1.84; 95% CI 1.07-3.16), having two or more contacts with a case manager prior to the 
intake visit at the drug treatment program (OR 2.47; 95% CI 1.33-4.59), having spent an 
average of 15 minutes or more with a case manager (OR 1.94; 95% CI 1.05-3.60), and 
being driven to treatment by a case manager (OR 4.94; 95% CI 2.19-11.4).16  While the 
primary outcome of this study (entering drug treatment) is not the same as our objective 
of PrEP initiation, the patient navigation intervention and SEP setting are the same as in 
our study. These findings demonstrate the added value of offering a patient navigation 
intervention for PWID from within a SEP, which we will apply in our study to promote 
PrEP initiation among PWID. Therefore, we will adopt the successful components of 
their case management approach in our study design, including multiple contacts with the 
PrEP navigator, visits greater than 15 minutes, and transportation assistance. 
The methodology previously described in the ARTAS trial has been closely 
replicated in at least four other studies.7-11 While the key populations and outcomes 
assessed across the five studies varied, the adapted patient navigation interventions were 
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successful in meeting each study’s primary objectives. Therefore, the ARTAS model is as 
an ideal framework to design our PrEP navigator intervention. The intervention will be 
adapted to meet the needs PWID in SEPs to promote our goal of increasing PrEP 
initiation within this population. All five studies offered a minimum of one patient 
navigation session with a maximum of five sessions.7-11 After the first session, 
participants had the option to attend four additional follow-up visits with the patient 
navigator to review personal strengths, reevaluate available resources, and focus on the 
remaining elements of the SBCM model.8 In ARTAS, all patient navigation contacts had 
to occur within 90 days of randomization.9 The length of each session varied between 
studies, ranging from 5 to 60 minutes.8,15 However, in the Strathdee et al. study, 
researchers found that participants who received 30 minutes or more of case management 
within 7 days from the baseline visit were 33% more likely to initiate treatment than 
those with sessions lasting less than 30 minutes.16 Given this finding, our initial session 
will be 45-60 minutes in length, modeled after the duration used in Doblecki-Lewis et al.  
Timeframe for Measuring Outcomes  
We will use a period of 12 weeks from the start of the PrEP navigation 
intervention as our timeframe for initiating PrEP. Studies by Reback et al. and Doblecki-
Lewis et al. used 12 week periods in their respective studies to evaluate linkage to PrEP 
and PrEP initiation.7,8 In an uncontrolled pilot trial of 19 MSM receiving a 2-session 
motivational interviewing intervention, 37% of participants obtained PrEP within one 
month.44 In a retrospective study evaluating time to PrEP initiation in primary care clinics 
in San Francisco, researchers found that PrEP users initiated PrEP after a median of only 
7 days, but there was a large minority of 29% that initiated PrEP between 30-90 days 
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after the patient navigation intervention.45 Given these findings, we would like to 
maximize the amount of time participants have to navigate the PrEP care continuum and 
initiate PrEP. Therefore, we will use 12 weeks as our cutoff point for determining 
successful PrEP initiation among our samples of PWID.  
Specifications of the PrEP Navigators 
The role of the patient navigator in previous studies has been occupied by 
community case managers, nurses, and study staff. Despite variations in the patient 
navigator identity, all studies provided specific training to personnel on how to deliver 
the patient navigation services. In Strathdee et al., all case managers underwent a 3-day 
training workshop on SBCM and the local resources available.16 Case managers were 
supervised by experienced social workers and each case manager held a case load of 
about 20 clients. The quality of the case management sessions was assessed via review of 
strength assessments, action plans, case logs, and group supervision checklists. On a 
monthly basis, case managers participated in group supervision sessions led by the 
Project Director, which involved presentation and discussion of challenging cases. The 
goal of all of these activities was to ensure a high degree of fidelity across the case 
management team. Each of the 10 SEP sites had one to three case managers.16 In Robles 
et al., the case management intervention was conducted by a registered nurse with 
intensive training in motivational interviewing strategies.17 A case manager with a 
bachelor’s degree in social work and training in the intervention protocol met with 
participants after each session to review lessons learned and provide assistance with 
overcoming any perceived barriers.17 
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Similarly, in the ARTAS trial, case managers were trained as a group prior to 
participant enrollment through an intervention manual.9 This is in contrast to Doblecki-
Lewis et al., which used trained study staff as patient navigators to deliver their SBCM 
intervention.8 For our purposes, the patient navigators will be community case managers 
with a minimum of a bachelor’s degree. They will undergo a multi-day training on how 
to apply strengths-based case management principles and motivational interviewing to 
their participant interactions, as modeled through multiple patient navigator studies.2,7-9  
2.4.6 Content of the Patient Navigation Intervention 
The core components of a SBCM intervention are engagement, strengths 
assessment, personal case planning, and resource acquisition.16 Engagement begins by 
developing a collaborative partnership between the patient navigator and the client, while 
reviewing the purpose of SBCM. The strengths assessment occurs at the first visit, where 
the navigator uses open-ended questions to record specific skills, talents, abilities, and 
behaviors of the participant. Personal care planning is the process of identifying short- 
and long-term goals for the participant, as well as referring them to community resources 
that address their identified needs and case management goals. In the resource acquisition 
component, the navigator will use information from the baseline needs assessment to 
identify client goals and help connect the client to services that address these goals.16  
Doblecki-Lewis et al. applied these same core principles to their patient 
navigation strategy.8 Following initial assessment, providers discussed available 
resources in the community for HIV prevention while supporting and motivating 
participants’ efforts to engage in these strategies. Navigators also took notes based on 
each participant’s encounter to record any barriers or facilitators to PrEP uptake. The 
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navigator then discussed strategies to overcome these barriers with the participant. There 
were also interviewer-administered assessments taken at baseline, 6 weeks, and 12 weeks 
of follow up. Measures included socio-demographics, experiences with PrEP, risk 
perception, risk behaviors, current prevention strategies, experiences with providers and 
clinics for HIV prevention care, perceived barriers and facilitators to obtaining PrEP, 
knowledge, beliefs and attitudes towards PrEP, adherence self-efficacy, health 
literacy/numeracy, depression, quality of life, and social support. Participants were asked 
at 4, 6, 8, and 12 weeks after the initial intervention if they had made an appointment 
with a PrEP provider or initiated PrEP.8  
The motivational interviewing patient navigation strategy used by Robles et al. 
addressed goal setting, decision making, reinforcement, and attitude change.17 Counselors 
would involve the participants in the decision process and explore discrepancies to reduce 
ambivalence towards drug treatment and HIV risk behavior change. Each of the 6 
sessions had a specific outline and design, focusing on topics such as participants’ plans 
for behavior change, drug use patterns, relapse prevention, and obstacles to change. 
Throughout the study, counselors and case managers followed a protocol for 
documenting all intervention sessions and completed monthly appraisals of participants’ 
progress. Six months after the baseline interview, participants were contacted by outreach 
workers and given a follow up assessment similar to the baseline survey.17  
The aforementioned studies describe the core structure of SBCM and motivational 
interviewing principles as they pertain to patient navigation approaches. Both 
components have shown success in PWID and can work synergistically to increase PrEP 
initiation as part of the patient navigation package.  
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2.4.7 Content of Control Condition 
The control condition, also known as the “enhanced standard of care,” includes a 
PrEP pamphlet with PrEP information and HIV prevention tools for participants. In 
Doblecki-Lewis et al., contents of this condition included a list of PrEP providers in the 
area, HIV testing sites, STI clinics, recommendations regarding initiating discussion with 
the provider regarding PrEP, and information regarding available financial assistance to 
assist with the cost of PrEP.8 This package ensured that participants in the control group 
received the same key information regarding PrEP access as the intervention group.  
In a PrEP implementation study targeting MSM, participants were provided with 
a one-page informational sheet which included clinical indications for PrEP, a description 
of PrEP treatment, common side effects, and compliance guidelines.29 In another PrEP 
uptake study among MSM, the control group participants received the same PrEP 
information listed in the study above plus printed educational materials from the CDC, a 
list of local PrEP providers, and PrEP copay assistance cards from the manufacturer.46 A 
review of these studies indicates that the key features of the PrEP pamphlet should 
include a PrEP overview, local PrEP providers, and the available financial resources.   
2.4.8 Outcomes  
The primary outcome of our study is PrEP initiation within 12 weeks of the 
intervention. This has been assessed in previous studies through periodic check-ins with 
participants to evaluate their progress in obtaining PrEP during the study. In Doblecki-
Lewis et al., participants were contacted at 4, 6, 8, and 12 weeks after randomization and 
asked if they had made an appointment with a PrEP provider or initiated PrEP.8 We will 
adapt this model to periodically track the progress of our participants at 4, 8, and 12 
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weeks. Once participants report PrEP initiation, they will be asked to come into the SEP 
within a week for confirmatory urine tenofovir metabolite testing, which will be able to 
detect both TDF and TAF formulations of PrEP. A urine tenofovir concentration of 
greater than 10ng/mL is suggestive of PrEP dosing within the last 7 days.47  
Secondary outcomes will assess HIV risk behaviors (needle sharing, sexual 
practices), awareness of PrEP and its function, likelihood of starting PrEP and perception 
of personal risk for HIV acquisition by group, before and after the intervention. These 
outcomes will be assessed with self-reported measures at baseline and post-intervention 
at week 12. Self-reported HIV risk behaviors regarding drug use and sexual intercourse 
during the past 30 days will be assessed using an adapted version of the HIV Risk-Taking 
Behavior Scale (HRBS).20 This 11-question scale has been shown to be a valid and 
reliable instrument for PWID and is designed for administration by an interviewer, which 
takes 10 minutes.48 The higher the score, the greater risk the subject has of contracting 
and/or transmitting HIV.48 Questions regarding PrEP awareness will be adapted from 
McFarland et al. (Appendix C).49 Likelihood of PrEP initiation will include “How likely 
are you to take a pill for PrEP each day to prevent HIV infection?” This question is 
adopted from a study seeking to increase PrEP uptake among black MSM.46 A Likert 
scale from 1 (very unlikely to take PrEP) to 5 (very likely to take PrEP) will be used. 
Perception of personal risk of HIV will be adopted from a PrEP implementation program 
for MSM in a STI clinic and asked as “How would you rate your risk for contracting 
HIV?” A Likert scale from 1 (extremely unlikely) to 5 (extremely likely) will be used.29 
These assessments will be collected at baseline through a structured 1-hour interview 
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with a trained study staff member.17 The same assessment will be repeated 12 weeks after 
the baseline interview. Appendix C contains the full assessment with all components. 
For those participants who initiate PrEP, an exploratory outcome will be sustained 
adherence evaluated at 18 weeks. Sustained adherence will be assessed via self-report 
and confirmatory testing, with participants indicating how consistently they took the 
medication (number of doses per week). In the landmark BTS, adherence criteria was 
defined as self-report of taking PrEP at least five days a week, with no more than two 
consecutive days off.38 The BTS also found that adherence is a key factor in determining 
the efficacy of PrEP in PWID.38 Sustained adherence can be confirmed via a tenofovir 
biomarker level with dried blood spots. Tenofovir is a component of the PrEP medication 
and persists in red blood cells with a half-life of approximately 17 days.47 Blood is 
collected via a fingerstick and a threshold of 700 fmol/punch in DBS indicates 
cumulative dosing of four or more doses of PrEP per week over the prior 6-8 weeks.47  
2.4.9 Review of Sample Size Calculation and Power  
Our sample size calculation was determined based on an appraisal of results from 
the randomized controlled trials of Gardner et al., Doblecki-Lewis et al., Samet et al., and 
Strathdee et al. In ARTAS, researchers assumed an absolute difference of 15-20% in 
linkage to care rates would be scientifically meaningful, and further assumed a 20% loss 
to follow up to perform their sample size calculation.9 Through their patient navigation 
intervention, they found a 15% absolute increase in linkage to HIV care at 6 and 12 
months compared to the standard of care passive referral group.9 While the linkage to 
care described in this study refers to connecting HIV-positive people who were not on 
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ART medications to HIV clinics, we can parallel their outcome of linkage to care with 
linkage to PrEP, which is part of the PrEP initiation process.  
In Doblecki-Lewis et al., researchers calculated sample size to detect a 25-30% 
absolute risk difference between their patient navigation and passive referral control 
groups.8 Overall, their results showed an absolute rate difference of 11% in PrEP 
initiation between both groups.8 While their study did not specifically look at PWID, it 
used a similar patient navigation intervention and specifically looked at the primary 
outcome of PrEP initiation. In Samet et al., researchers used a patient navigation 
intervention to link HIV-positive PWID to HIV care.11 They calculated sample size to 
provide 80% power to detect an absolute difference of 15% in proportions liking to HIV 
care.11 Results showed a 20% absolute rate difference between the intervention and 
control groups.11 While the study outcome of linkage to HIV care is not the same as ours, 
it was conducted in our target population of PWID, using patient navigation.  
Lastly, Strathdee et al. studied the effect of patient navigation on entry into drug 
treatment among PWID referred from SEPs.16 They found that the absolute rate 
difference in treatment entry within 7 days was 14% between the intervention and control 
groups.16 This study used PWID as the population, recruited from SEPs, and evaluated 
the effect of a patient navigation intervention. While treatment entry is not the same as 
PrEP initiation, it is a comparable outcome. Taking the results from all four of these 
studies, the average absolute rate difference seen is 15%, which has become our target 
difference in PrEP initiation rates between our intervention and control groups.  
Given this 15% absolute difference of effect, we must predict the initiation rates 
in the intervention and control group. Based on an extensive review of the literature, we 
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know that knowledge and use of PrEP in PWID is very low at baseline.50 Therefore, we 
predict that the rate of PrEP initiation in the control group that receives the PrEP 
information pamphlet and harm reduction standard of care will be 3%. Given the absolute 
rate difference of 15%, the rate of initiation in the intervention group with patient 
navigation is estimated to be 18%. When performing our sample size calculation, we will 
use a 2-tailed alpha of 0.05 and a power of 80%, while accounting for an estimated 20% 
loss to follow up. 
2.5 Conclusion:  
While knowledge of PrEP is critical to enable successful implementation, the 
mere provision of information about PrEP efficacy and access may not be enough to 
influence PrEP uptake in PWID.51 This emphasizes the need for an additional 
intervention such as patient navigation which utilizes subjective information such as 
perceived barriers to encourage participant action.51  The information presented in the 
literature review supports the promise of a patient navigation intervention to increase 
PrEP initiation among PWID. Our study design combines PrEP promotion and a patient 
navigation approach within a SEP to target the biobehavioral and structural environments of 
PWID. While there is data supporting the various components of our study design, there has 
yet to be a published study that introduces patient navigation in a SEP as a means of 
increasing PrEP initiation in PWID. Through our review of the literature, we have described 
the models that will inform use our study design, as well as the previous research 
demonstrating the need for this intervention. This project will add to the literature regarding 
the best approaches to increase PrEP uptake among PWID.  
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CHAPTER 3: STUDY METHODS 
3.1 Study Setting and Design: 
 
We will conduct an effectiveness study in the context of a multi-center, 
randomized controlled trial. We will be evaluating the effect of a PrEP navigation 
intervention on PrEP initiation rates among PWID. Our multi-site study will include 
PWID from four syringe exchange program sites in Connecticut: The Greater Hartford 
Harm Reduction Coalition, the New Haven Syringe Exchange, Apex Community Care in 
Danbury, and the Bridgeport Health Department Syringe Exchange Program. We will use 
a 1:1 randomization to assign participants to the intervention and control groups and 
stratify based on SEP site and insurance coverage. Due to the nature of the intervention, 
the participants and PrEP navigators cannot be blinded to group assignment. However, 
randomization assignment will be concealed from the follow-up assessors.   
3.2 Study Population, Sampling, and Recruitment: 
This study will recruit among PWID accessing services from four SEPs in 
Connecticut. We will use snowball sampling to identify PWID from the various SEPs, 
who will then be contacted and screened for the presence of inclusion and exclusion 
criteria. For individuals who meet criteria, study participation will be offered, and 
informed consent will be obtained. Upon informed consent, participants will complete 
interviewer-administered baseline assessments, which will include sociodemographic 
factors, PrEP awareness, risk perception, risk behaviors, and likelihood of starting PrEP.  
The ideal initial participants are people with diverse demographic characteristics 
known to belong to a large network of PWID. These individuals will be identified by 
employees of the SEP who are familiar with the individuals accessing its harm reduction 
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services. There will also be flyers within each SEP site for individuals to self-identify if 
interested (Appendix A). The initial participants will then be asked to recruit peers from 
their injecting networks who also identify as PWID that have access to the SEP. These 
peers are then screened for eligibility and consented to join the study and provide 
baseline data. The newly identified participants will then be asked to recruit more 
potential participants, and the process continues until a sufficient number of participants 
have been recruited to meet sample size requirements. All participants will receive $20 
USD as a cash incentive for each peer that they successfully refer into the study. Through 
our sampling process, we will obtain a population of HIV-negative PWID with qualifying 
risk factors for HIV who access a SEP. The inclusion and exclusion criteria are listed 
below in Table 1.  
Table 1: Inclusion and Exclusion Criteria  
 
Inclusion Criteria Exclusion Criteria 
CDC Criteria1: 
• Age ≥ 18 years old  
• Without acute or established HIV infection 
• Illicit drug injection within the past 6 months  
AND at least one of the following: 
• Any sharing of injection or drug preparation 
equipment in the past 6 months  
• Risk of sexual acquisition:  
o Anal sex without condoms 
o Bacterial STI in the last 6 months 
o Infrequent condom use with 1 or more 
partners of unknown HIV status or 
known to be at substantial risk for HIV 
o Ongoing relationship with an HIV-
positive partner  
Study Specific Criteria: 
• Must have accessed SEP services at least once 
in the last month  
• Able to meet with a navigator at the syringe 
exchange program  
• Ability to give informed consent  
• Willing to provide contact information and be 
contacted by phone  
• Any known renal dysfunction (CrCl <60 
ml/min)  
• History of HIV-positive test 
• Self-report of taking PrEP at baseline 
• Indications for post-exposure 
prophylaxis (PEP): 
o Exposure to bodily fluids 
within 72 hours that is known 
to be HIV-positive or at 
substantial risk for HIV  
• History of chronic HBV infection  
• Pregnancy  
• Signs or symptoms of acute HIV 
infection: 
o Fever  
o Fatigue  
o Myalgia/arthralgia  
o Skin rash 
o Headache 
o Pharyngitis 
o Cervical adenopathy 
o Night sweats  
o Diarrhea  
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HIV negative status will be evaluated at baseline with HIV antibody testing using 
the OraQuick Rapid HIV-1 antibody test in the absence of any signs or symptoms of 
acute HIV infection in the preceding month (see Table 1). Prior to PrEP initiation, 
participants must receive an assessment of their renal function and a test for HBV 
infection. As all participants in our study will need a visit with a PrEP provider to get a 
PrEP prescription, these additional tests will be conducted at the discretion of the 
respective PrEP provider.  
3.3 Participant Protection and Confidentiality:  
Prior to recruitment, we will obtain Yale Institutional Review Board (IRB) approval 
by submitting an application for approval of study design and safety. This application must 
be approved prior to the initiation of the study. In compliance with the Yale IRB application 
requirements, we will include an Authorization and Consent for Participation in Research 
Project 200 FR. 1 form. This form includes an invitation to participate in the study, 
description of the research project and procedures, potential risks and benefits, economic 
considerations, treatment alternatives, confidentiality and privacy agreements, and guidance 
on voluntary participation and withdrawal (Appendix B). All participants must be able to 
provide written, informed consent.  
All research investigators must complete a Health Insurance Portability and 
Accountability Act (HIPAA) training session and provide evidence of certification to the 
Yale IRB. All participants’ personally identifiable health information will remain protected 
under strict HIPAA compliance. Records collected throughout our study will be secured on 
an encrypted web-based data management system, only accessible by approved researchers 
requiring direct access to the information. To protect personal health information, each 
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participant’s file will be de-identified and codified. Once the analyses are complete, we will 
destroy all personal participant data.  
3.4 Study Variables and Measures:  
The independent variable is a standardized PrEP navigation intervention with a 
trained PrEP navigator. This intervention will include motivational interviewing and 
SBCM. The control variable will be an enhanced SEP harm reduction standard of care 
with a PrEP information pamphlet. The typical standard of care for a SEP is to provide 
sterile syringes and injection equipment to its clients. The dependent variable and 
primary outcome will be PrEP initiation rates in both groups, 12 weeks after 
randomization. PrEP initiation will be confirmed via self-report and a urine tenofovir 
concentration of greater than 10ng/mL. Secondary outcomes, assessed by self-report at 
baseline and week 12, include HIV risk behaviors (needle sharing, sexual practices), 
awareness of PrEP and its function, likelihood of starting PrEP, and perception of 
personal risk for HIV acquisition before and after the intervention (Appendix C). We 
will assess the average change in scores in these pre and post assessment measures 
between the control and intervention groups.  
For those participants who initiate PrEP, an exploratory outcome will be sustained 
adherence evaluated at 18 weeks after randomization. Adherence will be evaluated via 
self-report and confirmatory DBS testing, with participants indicating how consistently 
they took the medication (number of doses per week). By collecting blood from a 
fingerstick, we will use a threshold of 700 fmol/punch to represent a cumulative amount 
of four or more doses of PrEP per week over the last 6-8 weeks. 
3.5 Methodology: 
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3.5.1 Assignment of Intervention 
 
All participants will be assigned to either the intervention or control group 
through stratified randomization. The participants will be randomized using computer-
generated block randomization with randomly selected block sizes. Stratification will be 
by SEP site and insurance status. There will be a 1:1 allocation to intervention and 
control groups. Immediately following randomization, the control and intervention 
groups will receive their respective interventions. This ensures that all participants in the 
PrEP navigation group receive at least one in-person PrEP navigation session and that all 
members of the control group receive their PrEP information pamphlets. 
3.5.2 Intervention Design  
The PrEP navigation will include a minimum of one session, with the option to 
attend up to five sessions total. All PrEP navigation sessions must be completed within 
90 days of randomization. The mandatory initial session will be 45-60 minutes in length 
and the duration of subsequent sessions will vary based on participant needs. In the initial 
session, the PrEP navigator will utilize a structured and standardized manual that 
explores various SBCM concepts such as engagement, strengths assessment, personal 
case planning, and resource acquisition. The motivational interviewing component will 
weave in goal setting, decision making, positive reinforcement, and attitude change. The 
focus on this initial session will be to help participants explore identified risk behaviors 
and motivations towards initiating PrEP. The additional sessions will provide assistance 
with connecting to providers, transportation, scheduling appointments, and accessing 
prescriptions. Each PrEP navigator will have a copy of the baseline assessment as a 
reference during this session.  
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The PrEP navigators will be case managers from the community with a minimum 
of a bachelor’s degree. All PrEP navigators will attend a multi-day mandatory training on 
the principles and application of motivational interviewing and strengths-based case 
management. They will also learn how to deliver the standardized intervention manual 
objectives for the initial PrEP navigation session. The quality of the PrEP navigation 
sessions will be assessed by the project director via review of strengths assessments, 
action plans, and case logs. Participants in the PrEP navigation intervention group will 
also receive the PrEP pamphlet that the control group gets.  
3.5.3 Control Design  
Participants in the control group will receive a PrEP pamphlet and the SEP harm 
reduction standard of care. The PrEP pamphlet will be based on CDC materials regarding 
the risk of HIV in PWID, use of PrEP in PWID, local providers, prescription access, and 
financial assistance for PrEP (Appendix D). 
3.6 Data Collection:  
Data on the primary outcome of PrEP initiation rates will be collected at intervals 
of 4, 8, and 12 weeks after the time of the initial intervention in each group (PrEP 
navigation session vs. PrEP pamphlet). The research coordinators will ask participants 
whether they have made an appointment with a PrEP provider or initiated PrEP. This 
information will be collected by telephone calls made to each participant and their self-
reported answers. If participants report that they have initiated PrEP, they will be asked to 
come into the SEP site within a week for confirmatory urine tenofovir testing.  
An interviewer-administered baseline assessment that includes sociodemographic 
factors, PrEP awareness, risk perception, HIV risk behaviors, and likelihood of starting 
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PrEP will be collected at the beginning of the study after informed consent. This same 
assessment will be re-administered at the completion of the study, 12 weeks after 
randomization to assess secondary outcomes.  
Data for the exploratory outcome of sustained adherence will be collected at week 
18 weeks. This will be evaluated by self-report and a confirmatory DBS testing threshold 
of 700 fmol/punch. See Appendix E for the data collection form.  
3.7 Sample Size Calculation:  
 
Based on the review of the literature and adaptation of previous study results to 
our study setting, outcome, and population, the resulting absolute difference we predict 
between the intervention and control groups for PrEP initiation is 15%. From this data, 
we estimate the initiation rates in the intervention and control groups will be 18% and 
3%, respectively. For the given effect size (population proportions of 0.03 vs. 0.18), 
sample sizes would have to be 65 in each group (total 130) to reach a 2-tailed alpha of 
0.05 and a power of 80%. The justification for these values is informed by very low 
levels of PrEP initiation in PWID, especially in the SEP setting. As a baseline of PrEP 
initiation in the control group, we predict a 3% initiation rate through the PrEP pamphlet 
and harm reduction standard of care. Therefore, our predicted effect size for the 
intervention group is an 18% rate of PrEP initiation in participants receiving PrEP 
navigation. To maintain the ability to detect this effect size, we will also account for an 
estimated 20% loss to follow up which will increase our desired sample size to 156 
participants. See section 2.4.9 for a full justification of the calculation, and Appendix F 
for the calculation.  
3.8 Analysis:  
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Statistical analyses will be carried out by researchers blinded to group allocation. 
All data will be analyzed in an intention to treat approach, based on participants’ original 
group allocation. Statistical significance is defined as p<0.05 for all measurements. The 
primary outcome will be PrEP initiation by 12 weeks, reported as a dichotomous 
variable. Results will be compared via a chi square test for two unpaired samples. The 
PrEP adherence evaluation at 18 weeks will assess whether or not participants took the 
pill at least 4 days of the week in the preceding 6 weeks. Therefore, adherence will be 
operationalized as a dichotomous variable and compared via chi square.  
Baseline characteristics will be compared to ensure limited variation between the 
intervention and control groups. Continuous variables (age, mean HRBS score) will be 
reported as a mean and standard deviation and compared via student t-test. Categorical 
variables (gender, sexual orientation, education etc.) will be compared using a chi square 
test and reported as a proportion of the population. If we do find any differences between 
the control and intervention groups, we will adjust for any differences with a multiple 
logistic regression. The pre and post assessment will compare overall PrEP awareness, 
HIV risk behaviors, perception of HIV risk, and likelihood of starting PrEP, before and 
after the respective interventions in the treatment and control groups. We will assess the 
average change in these pre-post assessment measures between the control and 
intervention groups. These results will be analyzed using a Wilcoxon signed rank test for 
non-parametric paired samples and report the level of statistical significance.  
3.9 Timeline and Resources: 
The proposed study will be completed within the allotted two-year timeframe. We 
will allocate 3 months for the IRB approval process. All PrEP navigators will attend a 
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multi-day mandatory training on the principles and delivery of the standardized 
intervention manual objectives for the initial PrEP navigation session. This training will 
occur immediately after IRB approval, before enrollment begins. Participant recruitment 
and enrollment will begin at month 4 and will occur on a rolling basis over the course of 
12 months. After the 12 months, enrollment will stop but data collection will continue for 
an additional 5 months. This ensures that we obtain the 12-week PrEP initiation rates for 
the last participants recruited plus the additional 6 weeks needed to evaluate sustained 
adherence. There will be a 5-month period at the end of the study for data analysis. Table 
2 illustrates the proposed timeline.  
The study will take place at four SEP sites throughout the state of Connecticut. 
The personnel requirement for each study site will include: a research coordinator to 
enroll patients, two PrEP navigators to implement the intervention, a research assistant to 
follow up with patients and collect confirmatory labs, a project director to oversee the 
work of the PrEP navigators, and a research analyst to gather and organize the data. Each 
SEP site will have an office space reserved for the PrEP navigator to conduct the 
intervention visits. At the end of the study, the research analysts will help with data entry 
and statistical calculations.   
All participants will receive a $50 gift card as compensation for completion of the 
baseline and 12-week assessments. They will also receive $10 for giving their 
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1. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the 
Prevention of HIV Infection in the United States. 2017 Update: Clinical Practice 
Guideline.  Published March 2018. 
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X X X                      
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   X                     
Enrollment/ 
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                   X X X X X 
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CHAPTER 4: CONCLUSION 
4.1 Advantages and Disadvantages:  
Our proposed study design has a number of advantages. The effectiveness design 
delivers the PrEP navigation intervention in SEP settings that are already being utilized by 
PWID. Providing PrEP education and implementing PrEP navigation in the real-world 
settings of SEPs increases the generalizability of the intervention. Additionally, the PrEP 
navigation sessions are tailored to individual needs to help facilitate participants’ access to 
PrEP. This individualization provides a high degree of external validity with indications for 
broader implementation in other SEPs in the future. Lastly, the RCT design and use of 
stratified randomization limits bias, mitigates known and unknown confounders, and will 
describe the overall relationship between PrEP navigation and rates of PrEP initiation 
among PWID.  
  In terms of limitations, we know that the pathway from PrEP navigation to PrEP 
initiation requires several steps. While the purpose of the PrEP navigators is to help 
participants overcome barriers and increase access, previous studies have had high losses to 
follow up in PWID.1,2 While we account for loss to follow up in our sample size calculation 
and try to reduce it by ensuring participants are accessible by phone, it is hard to completely 
prevent and predict this challenge. Additionally, PrEP initiation does not always result in 
sustained PrEP adherence. However, given the low baseline uptake of PrEP in PWID and 
data supporting continued use after initiation, we hope that this can be an important first step 
for future studies.3 Lastly, our study’s SEPs are located solely within Connecticut in 
primarily urban areas where access to PrEP providers is relatively high.4 As a result, our 
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findings may not generalize to rural PWID or geographic areas where these services are not 
as accessible. 
4.2 Clinical and Public Health Significance:  
Research is urgently needed to understand how to package PrEP as a harm reduction 
tool that might be efficacious and make PWID more likely to engage in harm reduction 
techniques.5 The proposed study may help in addressing this critical gap in the literature 
about how best to reach PWID to promote PrEP initiation. Our study uses the evidence-
based successes of patient navigation for PWID and applies them in the community-based 
setting of SEPs to increase PrEP initiation. The overall clinical and public health 
significance of increasing PrEP initiation among PWID is a resulting reduction in HIV 
incidence. This public health benefit is consistent with the goals of current national 
initiatives to reduce the number of new HIV infections in the United States by 90% by 
2030.6 If this intervention is successful, it can provide insight on how PrEP navigation can 
be incorporated as part of the standard of care in SEPs in the future. The results of this study 
can also be a basis for future studies to target long-term PrEP use and adherence among 
PWID.  
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Appendix A: Recruitment Flyer  
 
 
Volunteers Needed for a Research Study 
 
Are you a person who injects drugs and uses services from a syringe exchange?  
 
We are conducting a research study to investigate whether a patient navigation 
intervention can help connect people who inject drugs to an HIV-prevention medication 
called pre-exposure prophylaxis or PrEP. 
 
Who is eligible?  
• People who inject drugs accessing a syringe exchange  
• Age 18+  
• HIV-negative  
 
 What will you have to do? 
• Receive education about a medication called pre-exposure prophylaxis or PrEP 
• Provide personal information regarding your HIV risk behaviors and 
knowledge/attitudes about PrEP  
• Be willing to meet with a PrEP navigator for at least 1 session  
 
Compensation: 
• Up to $135 as reimbursement for completion of assessments and collection of 
urine and blood samples  
 
To learn more or to see if you are eligible to participate:  

















































































































































































































































































































Appendix B: Compound Consent and Privacy Rule Authorization Form 
CONSENT FOR PARTICIPATION IN A RESEARCH STUDY 
200 FR. 1 (2016-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE  
 
Study Title: Promoting Pre-exposure Prophylaxis Among People Wo Inject Drugs 
Accessing Syringe Exchange Programs  
 
Principal Investigator: E. Jennifer Edelman, MD, MHS 
 
Invitation to Participate and Description of Project  
We are inviting you to participate in a research study designed to look at the effects of a 
standardized patient navigation intervention on pre-exposure prophylaxis (PrEP) 
initiation among people who inject drugs accessing syringe exchange programs. You 
have been asked to participate because you have met the inclusion criteria as an HIV-
negative person who injects drugs with risk factors for HIV. PrEP is a medication that 
can significantly reduce the risk of HIV acquisition in people who inject drugs by as 
much as 83%.  
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision. This consent 
form gives you detailed information about the research study, which a member of the 
research team will discuss with you. This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form.  
 
Description of Procedures  
If you agree to participate in this study, our research coordinator will ask you questions 
regarding your beliefs, risk behaviors and demographics. These will include questions on 
your PrEP awareness, risk behaviors, likelihood of starting PrEP, and HIV risk beliefs. 
We will also collect demographics such as age, gender identity, sexual orientation, 
race/ethnicity, education, income, employment status, insurance coverage, past PrEP use, 
medication use, history of sex work, and transportation needs.   
 
You will then be randomly assigned to receive (a) a patient navigation intervention with a 
PrEP navigator OR (b) a PrEP information pamphlet and the usual standard of care from 
the syringe exchange program. All participants will receive the PrEP information 
pamphlet regardless of group allocation. Randomization occurs through a computer-
based system in which you have equal chances of being assigned to the intervention or 
control group. Once you have been assigned to a group, you will be assigned a unique 
study code that will be used to identify you throughout the study.  
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If you are assigned to the PrEP navigation intervention, you will be asked to attend an 
initial session with a PrEP navigator, lasting 45-60 minutes. During the first session, the 
navigator will use a standardized manual to explore your strengths and perceived 
motivations or barriers towards PrEP initiation. You will have the option to attend up to 
five PrEP navigation sessions total and the length of each subsequent session will vary 
based on your needs. The additional sessions can provide assistance with connecting to 
providers, transportation, scheduling appointments, and accessing prescriptions.  
 
Research staff will contact you by phone at 4, 8, and 12 weeks after being randomized to 
receive either the intervention or control condition. At this time, you will be asked if you 
have made an appointment with a PrEP provider or initiated PrEP. If you report that you 
initiated PrEP, you will be asked to come into the syringe exchange within a week for 
confirmatory urine testing. At the 12-week mark after your intervention, we will repeat 
the assessment on your beliefs about PrEP and risk behaviors that you took at the 
beginning of the study. If you are confirmed to have initiated PrEP, you will be contacted 
again at 18 weeks to assess if you are still taking PrEP and how many times a week you 
take the medication. We will ask you to come into the syringe exchange program again to 
get a confirmatory fingerstick blood test.  
 
A description of this study is available on http://www.ClinicalTrials.gov, as required by 
U.S. Law. This Web site will not include information that can identify you. At most, the 
Web site will include a summary of the results. You can search this Web site at any time.  
You will be told of any significant new findings that are developed during the course of 
your participation in this study that may affect your willingness to continue to participate. 
If research results are published, your name and personal information will not be given.  
 
Risks and Inconveniences 
We identify very few physical risks, discomforts or inconveniences associated with the 
study. Some questions regarding your HIV risk behaviors ask for personal details about 
your sexual history and injection drug use, which might make you feel uncomfortable. 
These questions are not meant to judge you. They will be used to understand your risk 
behaviors that could potentially expose you to HIV. Other risks from participating in the 
study include the breach of confidentiality about your health status and participation in 
the study. This is very unlikely to occur, as all study investigators are trained and 
certified in research privacy. A minor inconvenience may be the monthly phone calls 
with a representative from the study. We also ask that you provide blood, urine and oral 
swab samples during the study to confirm HIV-negative status and PrEP use. The blood 
will be collected via fingerstick, which uses a sterile lancet to obtain a small quantity of 
capillary blood for testing. There are no major risks associated with this technique.  
  
Benefits 
The potential benefits of this study are connection to PrEP services and the initiation of 
PrEP medication, which can significantly reduce your risk of acquiring HIV as a person 




There are no costs associated with participation in the study. However, you will be 
responsible for the costs associated with the PrEP medication and PrEP provider visit per 
the health center’s policies. To mitigate these potential barriers, we have provided 
information on how to acquire PrEP at low cost or even free of charge. Depending on 
your insurance provider, you may be eligible for full coverage of these costs. 
Additionally, many of the medical providers listed on the PrEP provider guide will be 
able to offer assistance in signing up for health insurance and applying for payment 
assistance programs. As compensation for your participation in the study, you will 
receive $50 for each assessment you complete, $25 for a fingerstick sample, and $10 for 
a urine sample.  
 
Treatment Alternatives  
If you choose not to participate in this study, there are no alternative treatments available. 
If you are interested in PrEP but do not want to participate in this study, you may ask for 
more information from your primary care provider.  
 
Confidentiality and Privacy  
We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information. Any identifiable information that is obtained in 
connection with this study will remain confidential and will be disclosed only with your 
permission or as required by U.S. or State law. Examples of information that we are 
legally required to disclose include abuse of a child or elderly person, or certain 
reportable diseases, such as HIV or hepatitis. Information will be kept confidential by 
using only identification numbers on study forms, storing signed forms in locked 
cabinets, and password protecting data stored on a computer. When the results of the 
research are published or discussed in conferences, no information will be included that 
would reveal your identity unless your specific permission for this activity is obtained.  
 
The information about your health that will be collected in this study includes: 
• Research study records 
• Records about phone calls made as part of this research  
• Records about your study visits  
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who may need it for research purposes. All health care providers subject to 
HIPAA (Health Insurance Portability and Accountability Act) are required to protect the 
privacy of your information. The research staff at the Yale School of Medicine are 
required to comply with HIPAA and to ensure the confidentiality of your information.  
 
Voluntary Participation and Withdrawal  
Participating in this study is voluntary. You are free to choose not to take part in this 
study.  Refusing to participate will involve no penalty or loss of benefits to which you are 
otherwise entitled (such as your health care outside the study, the payment for your health 
care, and your health care benefits).  However, you will not be able to enroll in this 
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research study and will not receive study interventions as a study participant if you do not 
allow use of your information as part of this study. 
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part. This will cancel any 
future phone calls. The researchers may also withdraw you from participating in the 
research if necessary. When you withdraw from the study, no new health information 
identifying you will be gathered after that date. Information that has already been 
gathered may still be used and given to others until the end of the research study, as 
necessary to ensure the integrity of the study and/or study oversight.  There are no 
penalties involved with withdrawal from the study. 
 
Questions  
We have used some technical terms in this form. Please feel free to ask about anything 
you don't understand and to consider this research and the permission form carefully – as 
long as you feel is necessary – before you make a decision.  
 
Authorization 
I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. My 
signature also indicates that I have received a copy of this consent form.  
Name of Subject:_____________________________ 
Signature:___________________________________ 
Date:______________________________________  
___________________________________________ ___________________  
Signature of Principal Investigator Date  
or  
___________________________________________ ___________________  
Signature of Person Obtaining Consent Date  
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator.  
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688.  
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Appendix C: Baseline and Post Intervention Assessment   
Baseline and Post Intervention Assessment 
 
This assessment will be administered by a trained interviewer. It should take about 30 
minutes to complete.  
 
Participant Study ID: ________________  
 
Section 1: Baseline Demographics 
1) What is your age?  ______ 
2) What is your gender identity? (self-described) 
  Male   Female  Transgender Woman  Transgender Man   Other: _______ 
3) What is your sexual orientation? (self-described) 
 Heterosexual/straight   homosexual/gay/lesbian  bisexual  Other: _______ 
4) What is your ethnicity/race? (check all that apply) 
 White/Caucasian  Black/African American  Hispanic/Latino Other:_____ 
5) What is your education level? 
 Less than high school  High school graduate  More than high school  
6) What is your annual income?  
 <10k  10-19,999  >20k  
7) What is your employment status?  
 Employed  Unemployed 
8) Do you have health insurance? 
 Yes   No  
9) Have you ever used PrEP before?  
 Yes  No  
10) Do you take any prescription medications daily?  
 Yes  No  
11) Would you need assistance with transportation in order to get to a PrEP provider 
appointment?  
 Yes  No  
 
Section 2: HIV Risk Taking Behavior Scale (HRBS)1 
 
A. Drug Use Section:  
“I am going to ask you a few questions about your drug use over the last month…” 
 
1) How many times have you injected any drugs in the last month? 
None…………………………0 
Once a week or less………….1 
More than once a week………2 
(but less than once a day)  
Once a day……………………3 
2-3 times a day……………….4  
More than 3 times a day……...5  
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IF SUBJECT HASN'T INJECTED IN THE LAST MONTH, SCORE ZERO FOR THE 
DRUG USE SECTION, AND GO TO QUESTION 7.  
2) How many times in the last month have you used a needle after someone else had 
already used it?  
No times..................................... 0  
One time..................................... 1  
Two times................................... 2  
3-5 times .................................... 3  
6-10 times .................................. 4  
More than 10 times..................... 5  
 
3) How many different people have used a needle before you in the last month? 
None............................................0  
One person...................................1  
Two people .................................2  
3-5 people....................................3  
6-10 people..................................4  
More than 10 people....................5  
 
4) How many times in the last month has someone used a needle after you have used it?  
No times..................................... 0  
One time..................................... 1  
Two times................................... 2  
3-5 times .................................... 3  
6-10 times .................................. 4  
More than 10 times..................... 5  
 
5) How often, in the last month, have you cleaned needles before re-using them?  
Doesn't re-use............................. 0  






6) Before using needles again, how often in the last month did you use bleach to clean 
them?  
Doesn't re-use............................. 0  






Drug subtotal: ________ 
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B. Sexual Behavior Section:  
“I am going to ask you a few questions about your sexual behaviors over the last 
month…” 
 




3-5 people...................................3  
6-10people..................................4  
More than ten people .................5  
IF NO SEX IN THE LAST MONTH, SCORE ZERO FOR SEXUAL BEHAVIOR  
8) How often have you used condoms when having sex with your regular partner(s) in 
the last month?  
No regular partner .......................0  






9) How often did you use condoms when you had sex with casual partners?  
No casual partners .......................0  






10) How often have you used condoms when you have been paid for sex in the last 
month?  
No paid sex..................................0  






11) How many times did you have anal sex in the last month?  
No times..................................... 0  
One time..................................... 1  
Two times................................... 2  
3-5 times .................................... 3  
6-10 times .................................. 4  
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More than 10 times..................... 5  
 
Sexual Behavior Sub-total: __________ 
 
TOTAL SCORE: _________________ 
(drug use subtotal + sexual behavior subtotal)  
 
Section 3: Assessing PrEP Awareness2  
 
1)  Pre-exposure prophylaxis or PrEP is an antiretroviral medicine, such as 
Truvada®, taken for months or years by a person who is HIV negative to reduce 
the risk of getting HIV. Before today, have you ever heard of PrEP?  
 
2) Before today, did you know that PrEP can prevent the transmission of HIV from 
sharing injection equipment?  
 
3) In the past 12 months, have you had a discussion with a health care provider about 
taking PrEP? 
 
4)  In the past 12 months, have you taken PrEP to reduce the risk of getting HIV?  
 
Section 4: Likelihood of Initiating PrEP3 
 
1) How likely are you to take a pill for PrEP each day to prevent HIV infection?  
1- Very unlikely to take PrEP 
2- Unlikely to take PrEP 
3- Unsure  
4- Likely to take PrEP 
5- Very likely to take PrEP  
 
Section 5: Belief of one’s own risk of HIV4 
 
1) How would you rate your risk for contracting HIV?   
1- Extremely unlikely 
2- Unlikely 
3- Neutral  
4- Likely  
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Appendix E: Data Collection Sheet  
Outcomes Tracking Form 
 
 
Participant Study ID: ________________ 
 
PrEP Initiation Record 
 








Date of Reported PrEP Initiation: ____________ 
 
Confirmatory Urine Tenofovir Testing Results: ____________ 
 
Sustained Adherence Record  
 


























PrEP provider?  
Initiated PrEP?  
4 weeks Y/N  Y/N Y/N 
8 weeks Y/N Y/N Y/N 
12 weeks Y/N Y/N Y/N 
Follow up:  
Does the participant report that they have been taking the 
medication an average of 4 or more times a week?  
 
Y/N  
Confirmatory DBS Testing >700 fmol/punch? Y/N 
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Appendix F: Sample Size Calculation  
The following calculation was made using the Power and Precision Version 4 tool: 
 
Two-tailed test: 
Alpha (level of significance) = 0.05 
B (type II error) = 0.20, corresponding to a power of 80% 
 
 
For a given effect size (population proportions of 0.030 vs. 0.180), sample sizes (65 and 
65), and alpha (0.05, 2-tailed), power is 0.804. This means that 80% of studies would be 
expected to yield a significant effect, rejecting the null hypothesis that the two population 
proportions are equal.  
 
Factoring in an expected 20% loss to follow up, the total N = 156, with 78 participants in 
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